Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference
November 04, 2022 08:00 ET
|
Immutep Limited
Late-breaking abstract one of nine abstracts selected by SITC Communications Committee to be showcased at the SITC 2022 Press Conference Company to host Webcast on Thursday, 10th November...
Immutep Late-Breaking Abstract Accepted for Oral Presentation on First-in-Class LAG-3 Therapeutic Eftilagimod Alpha at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
November 02, 2022 08:00 ET
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company...
Immutep to Participate in Two Upcoming Investor Conferences
November 01, 2022 19:59 ET
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...
Immutep Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned
October 26, 2022 08:00 ET
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...
Immutep Quarterly Activities Report
October 25, 2022 08:00 ET
|
Immutep Limited
Media Release Clinical development strategy for efti to prioritise non-small cell lung cancer (NSCLC), as well as advance head & neck squamous cell cancer (HNSCC) and metastatic breast cancer...
Immutep Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
October 05, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies...
Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer
October 04, 2022 08:00 ET
|
Immutep Limited
Fast Track designation has been granted by the US FDA for efti in combination with pembrolizumab in 1st line non-small cell lung cancerBased on the encouraging Phase II clinical data for PD-L1...
Immutep to Participate in Two Upcoming Investor Conferences
September 26, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies...
Immutep Receives A$2.7 million R&D Tax Incentive from French Government
September 23, 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy...
Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha
September 14, 2022 08:00 ET
|
Immutep Limited
Encouraging Phase II data supports broad therapeutic potential of eftilagimod alpha in non-small cell lung cancer (NSCLC), head & neck squamous cell cancer (HNSCC) and metastatic breast cancer...